Nephrocare Health Care Services, Philippines Inc., a step-down wholly-owned subsidiary of nephrocare health services , has acquired assets relating to a dialysis center in the Philippines for PhP 151,600,000. The acquisition was made through an Asset Transfer Agreement (ATA) dated June 24, 2026, with Curis Dialysis and Kidney Care Center. The dialysis center is located at Orion, Bataan 2102 - Region III (Central Luzon), Philippines.

The transaction involves the purchase of identified assets for a total consideration of PhP 151,600,000. The agreement does not grant any special rights, such as the right to appoint directors or rights regarding share subscription. The seller, Curis Dialysis and Kidney Care Center, is not related to the promoter or promoter group of the company.

The disclosure was made to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The information is also available on the company's website. Kishore Kathri, Company Secretary & Compliance Officer, signed the disclosure on June 25, 2026.

Transaction Details

Nephrocare Health Services has disclosed that its overseas step-down wholly-owned subsidiary, Nephrocare Health Care Services, Philippines Inc., acquired identified assets relating to a dialysis center in the Philippines. The transaction, valued at PhP 80,640,000, was executed through an Asset Transfer Agreement (ATA) dated June 22, 2026, with Pag-Asa Dialysis And Diagnostic Center. The acquired center is located at Magsaysay St., Poblacion, Ipil, Zamboanga Sibugay, Philippines.

Transaction Details

The acquisition was undertaken to expand the company's operational footprint in the dialysis services segment. The consideration of PhP 80,640,000 was agreed upon subject to the terms and conditions outlined in the agreement. The disclosure was made to BSE Limited and National Stock Exchange of India Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory and Strategic Context

The filing confirms that the seller is not related to the promoter or promoter group of the company, and the transaction does not fall within related party transactions. There are no special rights attached to the agreement, such as the right to appoint directors or restrict capital structure changes. The acquisition aligns with the company's strategy to strengthen its presence in the international healthcare market.